This Article Full Text Full Text (PDF) Submit a related Letter to the Editor Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Copyright Permission Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Benvenga, S. Articles by Trimarchi, F. Search for Related Content PubMed PubMed Citation Articles by Benvenga, S. Articles by Trimarchi, F.

Thyroid Hormone Autoantibodies Elicited by Diagnostic Fine Needle Biopsy¹

Divisione di Endocrinologia, University of Messina School of Medicine, 98125 Messina, Italy

Address all correspondence and requests for reprints to: Dr. Salvatore Benvenga, Divisione di Endocrinologia, Policlinico Universitario, Padiglione H, via Consolare Valeria, 98125 Messina, Italy.

Based on the knowledge that diagnostic fine needle biopsy of the thyroid (FNAB) results in a prompt increase in circulating thyroglobulin (Tg), we evaluated whether Tg is indeed the postulated antigen for circulating antibodies against thyroid hormones (THAb). Preliminarily, we verified that FNAB causes the release into the bloodstream of iodinated, heterologous, and thus potentially immunogenic, molecules of Tg. Of the initially enrolled 400 patients, 214 had a number of blood drawings sufficient to evaluate over time (before FNAB and 1–3 h, 3 days, 15 days, 30 days, 3 months, 6 months, and 12 months after FNAB) the following parameters: THAb of both IgM and IgG classes, Tg antibodies (TgAb; by a sensitive immunoradiometric assay), and Tg (in the 156 patients who were TgAb negative).

We found the following. 1) Serum Tg most often peaks 1–3 h after FNAB (61 ± 45% of the baseline level; mean ± SD). 2) Only 7% of the initially TgAb-negative patients converted to positive, and only 12% of those initially positive had an increase in the levels of TgAb. 3) THAb were detected in 0 of 400 patients before FNAB, but were found in 9 of 214 (4.2%) after FNAB. This proportion is 2 orders of magnitude higher than that (149 of 369,000 or 0.04%) found in consecutive patients attending European thyroid clinics. Of the 9 cases, 6 had Hashimoto’s thyroiditis (HT), 2 had euthyroid colloid goiter, and 1 had Hurthle cell carcinoma. In the 5 of 9 cases who were TgAb negative, the post-FNAB increment in Tg was 21–99%, i.e. lower than that of the majority of patients (101–12,500%). 4) THAb were of the IgM class in all 9 (6 against T₃ and 3 against T₄), and were accompanied and/or followed up to 3 months after FNAB by IgG-THAb of the same specificity (2 against T₃ and 1 against T₄) in 3 cases. In a fourth case, IgM-T₃ were followed by a long-lasting synthesis of IgG-T₃ (i.e. up to 1 yr post-FNAB). All 4 cases with IgG-THAb had HT and remained TgAb positive. 5) In the 2 HT and the 3 non-HT patients with undetectable TgAb, THAb were of the IgM class only. 6) In the HT group, 2 risk factors for the development of post-FNAB THAb appeared to be pre-FNAB TgAb levels below 400 U/mL that did not increase after FNAB and Tg released from a colloid nodule.

We conclude that Tg release from the thyroid is sufficient to elicit THAb synthesis. In patients with autoimmune thyroid disease (HT), this synthesis occurs with a frequency 10-fold higher than that in patients with nonautoimmune thyroid diseases (21% vs. 2%). However, in only a fraction of patients with autoimmune disease, who need to be TgAb positive by a sensitive assay, the primary immune response (IgM) is followed by a secondary one (IgG). As, once present, this secondary response is long lasting in only a minority of our patients, we think that this could contribute to the rarity of naturally occurring THAb.

This article has been cited by other articles:

				S. Benvenga and F. Trimarchi Triggering of thyroid hormone autoantibodies J R Soc Med, January 1, 2003; 96(1): 50 - 50. [Full Text] [PDF]